GUIDANCE DOCUMENT FOR
VACCINES LOT RELEASE IN MALAYSIA

# GUIDELINE HISTORY

<table>
<thead>
<tr>
<th>No.</th>
<th>Description of amendment</th>
<th>Effective date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>First publication</td>
<td>1 July 2014</td>
</tr>
<tr>
<td>2</td>
<td>Revision of Guideline for Vaccine Lot Release</td>
<td>1 April 2015</td>
</tr>
<tr>
<td></td>
<td>First edition – July 2014</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Revision of Guideline for Vaccine Lot Release</td>
<td>1 December 2016</td>
</tr>
<tr>
<td></td>
<td>Second edition – April 2015</td>
<td></td>
</tr>
</tbody>
</table>
GUIDANCE DOCUMENT FOR APPLICANTS: 
INFORMATION AND SUBMISSION REQUIREMENTS FOR 
VACCINES LOT RELEASE

National Pharmaceutical Regulatory Agency
Ministry Of Health Malaysia
December 2016
NATIONAL PHARMACEUTICAL REGULATORY AGENCY (NPRA) MINISTRY OF HEALTH MALAYSIA

VISION:
TO BE A WORLD RENOWNED REGULATORY AUTHORITY FOR MEDICINAL PRODUCTS AND COSMETICS.

MISSION:
TO SAFEGUARD THE NATION’S HEALTH THROUGH SCIENTIFIC EXCELLENCE IN THE REGULATORY CONTROL OF MEDICINAL PRODUCTS AND COSMETICS.

OBJECTIVE:
TO ENSURE THAT THERAPEUTIC SUBSTANCES APPROVED FOR THE LOCAL MARKET ARE SAFE, EFFECTIVE AND OF QUALITY AND ALSO TO ENSURE THAT COSMETIC PRODUCTS APPROVED ARE SAFE AND OF QUALITY.
ACKNOWLEDGEMENTS

Advisor:
Siti Aida Abdullah
Acting Director of Pharmacy Regulatory
National Pharmaceutical Regulatory Agency
Ministry of Health Malaysia

Chief Editor:
Noorul Akmar Mohd Nur
Head of Centre for Quality Control

Members of Task Force Biological Lot Release Malaysia:
Noorul Akmar Mohd Nur
Dr. Noraida Mohamad Zainoor
  Hasniza Zaidan
Ahmad Syamsury Sulaiman
  Nik Juzaimah Juhari
Ida Syazrina Ibrahim
  Zarina Rosli
Nor Hayati Abd Rahim
Nor Hafizah Mohd Potri
Aida Haryati Abd Rahim
Dr Yvonne Khoo Siew Khoon
  Chiong Yuh Lian
Fazillahnor Ab Rahim
  Maslinda Mahat
Jenny Thong Chen Ni
  Nur Amani Shaari
Deborah Quah Ju Shan
Ahmad Izwan Abdul Rani
Special thanks to:
Aiza Adlina Abdullah
    Anis Talib
    Arpah Abas
    Dr Azizah Ab Ghani
    Fadhilah Hasbullah
    Dr Kamaruzaman Saleh
    Muhammad Lukmani Ibrahim
    Nora Ashikin Mohd Ali
    Poh Wen Tsin
    Sameerah Shaikh Abdul Rahman
    Sulaiman Haji Ahmad
    Tan Ann Ling
    Vidhya Hariraj
    Wan Mohaina Wan Mohammad

National Pharmaceutical Regulatory Agency
would like to express gratitude to the stakeholders and individuals for their contribution and assistance who have contributed in one way or another.
# TABLE OF CONTENTS

**ABBREVIATIONS AND ACRONYMS**.......................................................................................................................... 8

**GLOSSARY**................................................................................................................................................................. 9

**1.0 INTRODUCTION**..................................................................................................................................................... 11

  1.1 General Overview of Vaccine Lot Release............................................................................................................ 11
  1.2 Guiding Principles.................................................................................................................................................. 12
  1.3 Scope ................................................................................................................................................................... 12
  1.4 Scientific Guidelines Applicable to Vaccines Lot Release.......................................................................................... 13
  1.5 Implementation Timeline........................................................................................................................................ 13

**2.0 GUIDANCE FOR IMPLEMENTATION**.................................................................................................................... 14

  2.1 General .................................................................................................................................................................. 14
  2.2 Guidance on the Submission of Documents......................................................................................................... 16
    2.2.1 Application Form............................................................................................................................................... 17
    2.2.2 Lot Release Certificate...................................................................................................................................... 17
    2.2.3 Lot Summary Protocol....................................................................................................................................... 17
    2.2.4 Certificate of Analysis (COA) for Finished Products.......................................................................................... 17
    2.2.5 Importing Packing List....................................................................................................................................... 18
    2.2.6 Airway bill.......................................................................................................................................................... 18
    2.2.7 Criteria for requesting additional data................................................................................................................ 19
  2.3 Guidance on Temperature Monitoring.................................................................................................................... 19
  2.4 Guidance on Shake Test.......................................................................................................................................... 20
  2.5 Guidance on Non-Compliant Vaccines................................................................................................................... 20
  2.6 Guidance on Exceptional Case................................................................................................................................ 21
  2.7 Rejection Criteria for Vaccine Lot Release........................................................................................................... 23
  2.8 Guidance on Product Recall and Disposal.............................................................................................................. 24
  2.9 Decision making...................................................................................................................................................... 24
  2.10 Timeline............................................................................................................................................................... 24
  2.11 Fees...................................................................................................................................................................... 25
    2.11.1 Types of fees................................................................................................................................................... 25
    2.11.2 Mode of Payment............................................................................................................................................ 26

**3.0 REFERENCES**......................................................................................................................................................... 26

**4.0 APPENDIX**............................................................................................................................................................. 27

  4.1 Appendix 1: Application Form for Vaccine Lot Release............................................................................................ 27

**5.0 LIST OF UPDATES**.................................................................................................................................................. 29
ABBREVIATIONS AND ACRONYMS

BCG      Bacillus Calmette-Guérin (Tuberculosis Vaccine)
CQC      Center for Quality Control
CCL      Center for Compliance and Licensing
CDCR     Control of Drugs and Cosmetic Regulation 1984
DRGD     Drug Registration Guidance Documents
DPT      Diphtheria – Tetanus – Pertussis Vaccine
DT       Diphtheria – Tetanus Vaccine
EDQM     European Directorate for the Quality of Medicines & HealthCare
HepA     Hepatitis A Vaccine
HepB     Hepatitis B Vaccine
Hib      Haemophilus Influenzae Type B Vaccine
NCL      National Control Laboratory
NNC      Notification of Non-Compliance
NPRA     National Pharmaceutical Regulatory Agency
NRA      National Regulatory Authority
PRH(s)   Product Registration Holder(s)
SOP      Standard Operation Procedure
TRS      Technical Report Series
TT       Tetanus Toxoid Vaccine
VLR      Vaccine Lot Release
WHO      World Health Organisation
GLOSSARY

**Applicant (product registration holder):** The company or corporate or legal entity in the field of pharmaceuticals whose name the marketing authorisation has been granted. This party is responsible to all aspects of the product, including quality and compliance with the conditions of marketing authorization. The authorised holder must be subjected to legislation in the country that issued the marketing authorisation, which normally means being physically located in that country (1)

**Combination vaccine:** Vaccine with more than one antigen, combined in a single injection, e.g. DPT vaccine combining diphtheria, pertussis and tetanus antigens (2)

**Licensed importer:** A person to whom an import license has been issued under Regulation 12, CDCR 1984 (3)

**Licensed wholesaler:** A person to whom a wholesaler's license has been issued Regulation 12, CDCR 1984 (3)

**Lot:** A defined quantity of starting material, packaging material, or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a lot into a number of sub-lots, which are later accumulated to form a final homogeneous lot. In continuous manufacture, the lot must correspond to a defined fraction of the production, characterised by its intended homogeneity. The lot size can be defined either as a fixed quantity or as the amount produced in a fixed time interval (4)

**Lot release:** The process of NRA/ NCL evaluation of an individual lot of a licensed vaccine before giving approval for its releasing onto the market (4)

**Lot summary protocol:** A document summarising all manufacturing steps and test results for a lot of vaccine, certified and signed by the responsible person of the manufacturing company (4)

**Monovalent vaccine:** A monovalent vaccine contains a single strain of a single antigen, e.g. Measles vaccine (2)

**Non-compliance:** Failure or refusal to comply with a standard or a set of limits (4)
**NRA/ NCL:** The NRA/ NCL taking the responsibility for regulatory oversight of a product for the critical regulatory functions defined by WHO, including independent lot release. Usually it is the country of manufacture unless specific agreements exist within defined territories such as in European Union where the ‘country’ of manufacture is the European Union and the activity of the responsible NRA/ NCL is designated from among the Member States (4).

**Polyvalent vaccine:** A polyvalent vaccine contains two or more strains/serotypes of the same antigen, e.g. Oral Polio Vaccine (2)

**Prequalified vaccine:** A vaccine that has been approved as acceptable, in principle, for purchase by United Nations agencies, such as WHO, after full assessment of all procedures involved in its production. The purpose of the assessment is to verify that prequalified vaccines: (a) meet the specifications of the relevant UN agency; and (b) are produced and overseen in accordance with the principles and specifications recommended by WHO, for good manufacturing practice (GMP), and for good clinical practice (GCP). This is to ensure that vaccines used in national immunisation services in different countries are safe and effective for the target population at the recommended schedules and that they meet particular operational specifications for packaging and presentation (4).

**Reference country:** The reference country for Malaysia is listed as per the latest version of Drug Registration Guidance Document by National Pharmaceutical Regulatory Agency (1)
1.0 INTRODUCTION

Vaccine is an antigenic substance that is administered into human intended to produce immunity to a disease by stimulating the production of antibodies. It is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, sub-unit vaccines, polysaccharide vaccines, conjugated vaccines and recombinant vaccines. Production of vaccine is complex, arduous and requires a mastery of multiple technologies. Therefore, strict quality control and monitoring at every stage of process are mandatory in order to eliminate or reduce the risk due to production failures.

This guidance document is intended to facilitate local stakeholders to understand and meet the requirements for vaccine lot release in Malaysia.

1.1 General Overview of Vaccine Lot Release

Vaccine is a biological product used in healthy populations. It is given in a mass population, involving healthy babies and young children. Vaccine is complex in nature and more variable than chemically synthesised drug. The challenges in producing consistent lots of vaccines have raised doubts toward safety of vaccines. Different lot of vaccine is developed from inherently variable biological source and may cause deleterious effects such as reversion to virulence or toxicity or loss of immunogenicity. Since these effects may not be detected immediately after administration, major consequences may arise because vaccinations involve large number of healthy persons. Moreover, with the increasing number of people having doubts with the safety and success of national immunisation programme, any problems regarding the safety issues of vaccine would further tarnish the public trust on the public health strategies.

In addition to the manufacturing complexity, proper storage condition and efficient supply chain management must be ensured to preserve the sensitivity and limited shelf life properties of vaccine.

For these reasons, a careful independent review of manufacturing and quality control data on every lot is necessary before it is marketed. This is to ensure the consistent quality of manufactured lots.

Each vaccine lot is subject to the lot release programme before it is released onto the market. The PRH or importer must submit relevant documents or samples to NRA for independent assessment. Manufacturers must ensure that every new lot of vaccine is identical in its specific characteristics as outlined in the approved marketing authorisation.
Lot release programme will enable NRA to ascertain the safety and effectiveness of every lot of vaccines produced. Upon approval from the NRA, a formal release letter or certificate will be issued to allow release onto the market.

Independent assessment of vaccine can be based on:
   a) review of manufacturers' summary protocols, which include manufacturing and testing data for each manufactured lot of the product
   b) recognition/ acceptance of lot release certificate from responsible National Regulatory Authority
   c) assessment of cold chain system monitoring
   d) testing that is independent of the manufacturers’ quality control testing

These approaches are not mutually exclusive and may be product-specific. Where appropriate, strategy for each particular vaccine shall be established by taking into consideration aspects such as the nature of vaccine, the post-market experience including production history and safety profile.

1.2 Guiding Principles

Our main intention is to safeguard public health and their well-being. The lot release programme provides an additional monitoring on each newly manufactured lot of vaccine. The approach employed in this programme is based on the recommendations by World Health Organisation (WHO).

1.3 Scope

This guideline is focused on registered imported vaccines for human use. This document is intended to provide guidance to vaccine PRHs, importers and wholesalers.

The content of this guideline will be reviewed and amended accordingly in the future for locally produced vaccine.
1.4 **Scientific Guidelines Applicable to Vaccines Lot Release**


1.5 **Implementation Timeline:**

The vaccine lot release was implemented according to a phased timeline established by National Pharmaceutical Regulatory Agency (NPRA). The implementation was conducted in 2 phases as follow:

a) **Pilot study:** Vaccine (either combination or single antigen vaccine) which consists of Bacillus Calmette-Guérin (BCG), Diphtheria, Tetanus, Pertussis (DTP), Hepatitis B (HepB), Haemophilus Influenzae Type B (Hib), Polio and Human Papillomavirus (HPV). – Effective on 1st July 2014

b) **Full implementation:** Other antigens (either combination or single antigen vaccine) that are not stated in Phase 1 such as Hepatitis A (HepA), Influenza, Measles, Rubella, Rabies, Yellow Fever, Typhoid, Japanese Encephalitis, Varicella, Rotavirus, Zoster, Cholera, Meningococcal, Pneumococcal and others. – Effective on 1st January 2015.

Under both phases, monitoring of cold chain system is mandatory before releasing the vaccines onto the market.
2.0 GUIDANCE FOR IMPLEMENTATION

2.1 General

This guideline is largely based on the recommendation outlined in the Guidelines for Independent Lot Release of Vaccines by Regulatory Authorities (4). The lot release approaches for registered imported vaccines in Malaysia include:

a) Review of manufacturer’s summary protocol based on product dossier which has been approved by NPRA during product registration,

b) Review of cold chain system monitoring and appropriate data e.g. thermal cycling studies and shipping validation data which have been evaluated.

The Process Flow 1 diagram (below) illustrates the processes involved vaccines lot release. The process will involve the following parties:

a) Applicants (PRH)
b) National Pharmaceutical Regulatory Agency (NPRA)
c) Importers and
d) Wholesalers.
Process Flow 1: VACCINE LOT RELEASE PROCESS

START

PRH to submit application form and documents in section 2.2

14 working days before product arrival at warehouse

CQC to provide confirmation amount of payment to PRH

PRH to make payment at Unit Kewangan, NPRA before product arrival

CQC to inform CCL the date of product arrival at warehouse

CCL to conduct cold chain inspection & physical check at warehouse

Product arrival at warehouse

Within 2 working days

Evaluation satisfactory?

YES

CQC to evaluate lot summary protocol

CQC to inform CCL the date of product arrival at warehouse

CCL to conduct cold chain inspection & physical check at warehouse

Within 6 working days after arrival at warehouse

Inspection satisfactory?

YES

PRH to submit evidence of collection for disposal to CQC

Within 90 days after date of collection

CQC to provide confirmation amount of payment to PRH

PRH to make payment at Unit Kewangan, NPRA before product arrival

Within 30 days after issuance of notification

Decision by Director of NPRA

END

Yes

CQC to evaluate additional documents

Satisfactory?

YES

CQC to issue Lot Release Certificate to PRH

END

NO

CQC to correspond with PRH for additional documents

CQC to correspond with PRH for additional documents

Internal discussion / consultation

Satisfactory?

YES

CQC to issue Notification of Non-Compliance to PRH

PRH to submit evidence of disposal to CQC

Within 90 days after date of collection

NO

Within 30 days after issuance of notification

LEGEND:
PRH: Product Registration Holder
CQC: Centre for Quality Control
CCL: Centre for Compliance and Licensing
General Procedure of Vaccine Lot Release in Malaysia:

i. Applicant submits application form (refer to Appendix 1) and documents (refer to section 2.2) via email to CQC (vaccineCQC@npra.gov.my).

ii. NPRA will respond to the email by providing confirmation on the amount of fee to be paid. Please refer to section 2.11.1 of the guideline for further details on fees.

iii. Before product arrival, applicant makes payment to NPRA.

iv. Evaluation of summary protocol is conducted.

v. Within 2 working days after the arrival of vaccines at warehouse, NPRA’s officer will conduct cold chain inspection and verify physical appearance of the vaccines.

vi. NPRA will issue lot release certificates if all the requirements have been fulfilled, within 6 working days after product arrival at warehouse.

vii. If the requirements are not met, NPRA will issue notification of non-compliance to reject the vaccines.

viii. In the event of non-compliance, it is the sole responsibility of the PRH to ensure proper safe disposal of the vaccines. A copy of collection for disposal documentation shall be sent to NPRA within 30 days after issuance of rejection and a copy of disposal documentation shall be sent to NPRA within 90 days after the collection date.

ix. Lot summary protocol for the same lot number being imported into the country at different times will not be evaluated again. However, cold chain inspection will still be conducted.

x. For cases stated in (ix), PRH should only submit the VLR application form, import packing list, airway bill and make payment for cold chain inspection.

2.2 Guidance on the Submission of Documents

This guidance outlines the general requirement for documents submission. All the documents shall be written in Bahasa Malaysia or English only. Each document must be clearly tagged (indexed and labelled). Documents to be submitted are:

a) Application Form
b) Lot Release Certificate
c) Lot Summary Protocol
d) Certificate of Analysis (COA) for Finished Products
e) Importing Packing List
f) Airway bill.

Incomplete submission of documents may result in rejection of the application. Importing packing list and airway bill may be submitted two working days before product arrival.
2.2.1 Application Form

a) Application form is available in NPRA official website (refer to Appendix 1) and applicant shall use the same form without any amendment of the format
b) All sections shall be filled by applicant except section “For Office Use only”
c) Incomplete form will not be processed
d) The application form shall be submitted to CQC via email: vaccineCQC@npra.gov.my
e) The lot number (in final packaging) stated in the application form must be identical to the lot number on the lot summary protocol, lot release certificate and certificate of analysis.

2.2.2 Lot Release Certificate

Lot release certificate provided should be issued by the NRA from the country of origin.

In the event where the NRA does not provide a release certificate, and the vaccine is not a WHO prequalified vaccine, lot release certificate from any of the NPRA’s eight (8) reference countries (United Kingdom, Sweden, France, United States of America, Australia, Canada, Japan and Switzerland) will be accepted.

For list of WHO prequalified vaccine, kindly refer to WHO website: [http://www.who.int/](http://www.who.int/).

2.2.3 Lot Summary Protocol

The evaluation of the summary lot protocol will be based on dossier (Chemistry, Manufacture and Controls) which has been evaluated and approved by NPRA during product registration.

2.2.4 Certificate of Analysis (COA) for Finished Products

All release tests and its specification shall be the minimum requirement. Certificate of analysis for finished products may contain the following information:

a) name of manufacturer
b) product name, dosage form and strength
c) lot number (must be parallel to the lot number in the application form)
d) date of expiry
e) date of manufacture
f) list of tests
g) specification of tests
h) result of tests
i) approval from responsible person.
2.2.5 Importing Packing List

Applicant shall provide the details of importing packing such as:

a) date of shipment,
b) port of loading and discharge,
c) container numbers,
d) numbers and types of package,
e) gross weight (kg),
f) dimension Height x Width x Length (cm),
g) quantity,
h) description of goods and
i) other information related to the shipment.

The importing packing list must be submitted to CQC two (2) working days before the product arrival.

2.2.6 Airway bill (AWB)

For vaccine transported via air route, applicant shall provide the details of AWB such as:

a) Airway bill number
b) Airport of departure
c) Airport of destination
d) Flight number and date of arrival
e) Shipper’s Name and Address
f) Consignee’s Name and Address
g) Total number of packages
h) Description of goods

The airway bill must be submitted to CQC two (2) working days before the product arrival.
2.2.7 Criteria for requesting additional data

NPRA shall request additional data from PRH under conditions including but not limited to:

- a) data provided are not reliable
- b) insufficient information to support the evidence of the data (such as unavailability of raw data to support the results)
- c) trending analysis data is out of normal trends (in this case, validation data for each parameter should be provided)
- d) information of reference standard is not available (such as source of standard, procedure to produce standard and method used to standardise the standard)
- e) NRA from the country of origin/ NPRA’s reference countries does not issue lot release certificate or the vaccine is not a WHO prequalified vaccine.

Under condition (e), applicant shall provide all the testing raw data for the whole manufacturing process. Submission of requested data is mandatory for the first lot release application.

2.3 Guidance on Temperature Monitoring

Deviation of temperature or incorrect storage condition of vaccine may affect the quality, efficacy and subsequently the safety of vaccine. Hence, it is recommended that all vaccine products should be stored in their respective recommended condition at all times with continuous monitoring. Failure to show the traceability of temperature monitoring and appropriate storage condition may result in rejection of the entire lot of vaccine.

To facilitate the Cold Chain Inspection on arrival of product, suitable electronic temperature monitoring devices should be included in all shipments to document whether temperature limits have been exceeded. These devices shall serve as a quick reference to determine whether the shipment has been exposed to temperature at which products could have been damaged.

As temperature deviation could happen during transportation or redressing, PRH must submit relevant data and supporting document such as thermal cycling studies and shipping validation to justify temperature excursion for each product. The data must be sufficient to prove that the vaccine products remain stable at those storage conditions. All data must be submitted and will be evaluated by CCL. If the supporting documents or data provided is not sufficient to show evidence of product stability, the vaccine lot shall be rejected.
Please refer to the Guidelines on Good Distribution Practice (GDP) and Supplementary Notes for Management of Cold Chain Products/Material for further details on vaccine temperature monitoring.

### 2.4 Guidance on Shake Test

In the event of an adsorbed vaccine (DPT, DT, TT, Hep B, Hib liquid and/or combination of these) is suspected to be exposed to a freezing temperature, shake test shall be conducted by NPRA officers in NPRA laboratories. It is the responsibilities of the PRH to ensure the vaccine is transported to NPRA laboratories at an advised date by NPRA.

Vaccine to be used for shake test shall be taken based on a random sampling from the same lot of the affected vaccine, by NPRA. Vaccine used in the shake test shall not be returned to the PRH.


### 2.5 Guidance on Non-Compliant

#### 2.5.1 Non-compliant vaccine

In the event of non-compliant vaccine, the PRH shall ensure that the supply of the vaccine for the local use will not be affected.

The PRH shall ensure that non-compliant vaccines are not released onto the market and will be disposed in Malaysia. PRH shall provide appropriate proof of collection for disposal within 30 days after issuance of non-compliance notification and proof of disposal within 90 days after the date of collection.

#### 2.5.2 Non-compliant product importer or wholesaler

Failure of importer or wholesaler to meet the requirement of Good Distribution Practice may result in revocation of import or wholesale license. In such cases, the PRH shall have a contingency plan to ensure that the supply of the vaccine for the local use will not be jeopardised.
2.6 Guidance on Exceptional Case

This guidance shall only apply to the emergence of crisis situation such as pandemic, epidemic, the shortage of product on the market or an urgent need due to changes in national health policy recommendation.

Exceptional case application shall be supported by related documents. It is not applicable as an alternative plan to support improper supply planning and handling of stock by applicant.

The Process Flow 2 diagram (below) illustrates the process of vaccines lot release system under exceptional case.

For other situations in which releases of vaccine lot need to be conducted immediately, it will be handled on case-to-case basis.
Process Flow 2: LOT RELEASE PROCESS FOR EXCEPTIONAL CASE

START

Send a letter to request the lot of vaccine to be categorised under exceptional case

Follow general procedure under section 2.1

NO

Request granted by NPRA?

YES

PRH to submit application form, documents in section 2.2, payment to CQC & arrange shipment of vaccine

Product arrival at warehouse

CQC to conduct priority review on documents submitted

CCL to conduct cold chain inspection at warehouse

Evaluation & inspection satisfactory?

NO

Within 30 days after issuance of notification

CQC to issue Notification of Non-Compliance to PRH

Within 90 days after date of collection

PRH to submit evidence of disposal to CQC

END

YES

CQC to issue Lot Release Certificate to PRH

END

LEGEND:
PRH: Product Registration Holder
CQC: Centre for Quality Control
CCL: Centre for Compliance and Licensing
NPRA: National Pharmaceutical Regulatory Agency
**General Procedure for Exceptional Case:**

i. Applicant sends a requisition to Director of NPRA with accompanying justification for exemption case.

ii. If the request is accepted, applicant submits application form (refer to Appendix 1) and documents (refer to section 2.2) via email to CQC (vaccineCQC@npra.gov.my).

iii. NPRA will respond to the email by providing confirmation on the amount of fee to be paid. Please refer to section 2.11.1 of the guideline for further details on fees.

iv. Before product arrival, applicant makes payment to NPRA.

v. Priority review on all the documents submitted will be conducted.

vi. Upon the arrival of vaccines at warehouse, NPRA shall conduct cold chain inspection.

vii. If the evaluation and inspection are satisfactory, NPRA shall issue lot release certificate.

viii. In the event of unsatisfactory evaluation or inspection of the respective lot, NPRA shall issue a non-compliance notification (NNC). A copy of collection for disposal documentation shall be sent to NPRA within 30 days of issuance of rejection. A copy of disposal documentation shall be sent to NPRA within 90 days after collection date.

ix. Lot summary protocol for the same lot number being imported into the country at different times will not be evaluated again. However, cold chain inspection will still be conducted.

x. For cases stated in (ix), PRH should only submit the application form, make payment for cold chain inspection and submit importing packing list.

### 2.7 Rejection Criteria for Vaccine Lot Release

Lot of vaccine shall be rejected under conditions including but not limited to:

a) decision from Director of NPRA based on the supporting document, comments from other NRA (if available) and summary from evaluator

b) failure to commit the requirement of cold chain management with no supporting data for temperature excursion

c) unseal of vaccine/quarantine vaccine without approval from NPRA

d) failure in physical appearance check during inspection with no supporting data

e) failure to provide additional data requested during evaluation or inspection

f) the product information leaflet and label are not updated accordingly or updated without NPRA’s approval (approval for product variation by NPRA shall be received before the submission of lot release)
2.8 Guidance on Product Recall and Disposal

Please refer to the Guideline on Good Distribution Practice for further details on product recall and disposal.

2.9 Decision making

All the decisions made by NPRA are final and no appeal shall be allowed in any circumstances. The reason(s) of non-compliance will be clearly stated in the non-compliance certificate.

2.10 Timeline

Table 1 below shows the timeline for each activity in the lot release process.

Table 1:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission of application form and documents in section 2.2.1 – 2.2.4</td>
<td>14 working days before arrival of vaccines at warehouse</td>
</tr>
<tr>
<td>Payment for vaccine lot release</td>
<td>Within 14 working days before arrival of vaccines at warehouse</td>
</tr>
<tr>
<td>Submission of import packing list and airway bill (Section 2.2.5 and 2.2.6)</td>
<td>2 working days before arrival of vaccines</td>
</tr>
<tr>
<td>Conduct cold chain inspection</td>
<td>Within 2 working days after arrival of vaccines at warehouse</td>
</tr>
<tr>
<td>Issue of lot release certificate</td>
<td>Within 6 working days after arrival of vaccines at warehouse</td>
</tr>
<tr>
<td>Submission of evidence of collection for disposal in the event of non-compliance</td>
<td>Within 30 days after issuance of notification of non-compliance</td>
</tr>
<tr>
<td>Submission of evidence of disposal in the event of non-compliance</td>
<td>Within 90 days after date of collection for disposal</td>
</tr>
</tbody>
</table>
2.11 Fees

Every application for vaccine lot release shall be charged. Payment made shall NOT be REFUNDABLE once the application has been submitted and payment confirmed. Applications without the correct fees will not be processed.

2.11.1 Types of fees

The fees imposed for vaccine lot release are shown in Table 2 and Table 3. The evaluation fee will be waived if the same lot of vaccine arrives at different times.

Table 2: Fee for West Malaysia:

<table>
<thead>
<tr>
<th>Type of Vaccine</th>
<th>Cold Chain Inspection and Evaluation of Lot Summary Protocol</th>
<th>Cold Chain Inspection for Lot Summary Protocol has been evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monovalent vaccine</td>
<td>RM300/vaccine lot</td>
<td>RM200/vaccine lot</td>
</tr>
<tr>
<td>Polyvalent vaccine</td>
<td>RM500/vaccine lot</td>
<td></td>
</tr>
<tr>
<td>Combination vaccine</td>
<td>RM1000/vaccine lot</td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Fee for East Malaysia:

<table>
<thead>
<tr>
<th>Type of Vaccine</th>
<th>Cold Chain Inspection and Evaluation of Lot Summary Protocol</th>
<th>Cold Chain Inspection for Lot Summary Protocol has been evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monovalent vaccine</td>
<td>RM600/vaccine lot</td>
<td>RM500/vaccine lot</td>
</tr>
<tr>
<td>Polyvalent vaccine</td>
<td>RM800/vaccine lot</td>
<td></td>
</tr>
<tr>
<td>Combination vaccine</td>
<td>RM1300/vaccine lot</td>
<td></td>
</tr>
</tbody>
</table>

2.11.2 Mode of Payment

The processing fee and any other charges shall be paid in the form of cash/ credit card/ bank draft/ banker’s cheque/ money order/ postal order made payable to “Biro Pengawalan Farmaseutikal Kebangsaan”.
3. REFERENCES


## 4. APPENDIX

Appendix 1: Application Form for Vaccine Lot Release

![Application Form for Vaccine Lot Release](image-url)
5. TRANSPORTATION OF VACCINE

5.1 Arrival date

5.2 Transit point (if any)

5.3 Route of transportation
- [ ] Air
- [ ] Ocean

5.4 Mode of transportation
- [ ] Active system
- [ ] Passive system

6. DOCUMENTATION

6.1 Documents submitted
- [ ] Lot Summary Protocol
- [ ] Lot Release Certificate
- [ ] Certificate of Analysis of Finished Product
- [ ] Importing Packing List
- [ ] Air Way Bill / Sea Way Bill

7. REDRESSING / REPACKING/RELABELLING INFORMATION

(ONLY APPLICABLE FOR MAL NO. WITHOUT SUFFIX - R)

7.1 Do these product require redressing/repacking/relabelling?
- [ ] Yes. Refer to 7.2
- [ ] No

7.2 Have you submitted a request letter to conduct ANY redressing/repacking for these products to the Regulatory Coordination Section, Centre for Product Registration (SKR PPF)?
- [ ] Yes. Submission date:
- [ ] No

The Malaysian Drug Registration Guidance Document defines redressing, repacking and relabelling as a manufacturing activity. Manufacturing of products without a valid manufacturing license is an offense under Control of Drugs and Cosmetics Regulations 1984 [Regulation 12(1)]

8. APPLICANT DECLARATION

I hereby certify that the above information given are true and correct as to the best of my knowledge. I understand that if any of the above information is found to be false or untrue or misleading or misrepresenting, I am aware that I may be held liable for it, this application will be rejected and any payments made will not be refunded.

Remarks:

Name ____________________________ Signature ____________________________ Date __________

FOR OFFICE USE ONLY

VLR Documents complete?
- [ ] YES
- [ ] NO. List of pending documents:
  - [ ] LRC
  - [ ] COA
  - [ ] AWR/SWB
  - [ ] Importing Packing List

No. bil. SAB: Bil ( ) SFPK/ PKK/16/01
Amount:
- [ ] RM200
- [ ] RM300
- [ ] RM500
- [ ] RM1000

Date of issuance: ____________________________ Issued by, date & signature ____________________________

Date of payment received: ____________________________ Receipt no.: ____________________________ Received by, date & signature ____________________________
## 5. LIST OF UPDATES

<table>
<thead>
<tr>
<th>NO.</th>
<th>REVISION</th>
<th>SECTION/APPENDIX</th>
<th>UPDATES</th>
<th>DETAILS</th>
<th>REFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>April 2015</td>
<td>1.4</td>
<td>Removal of information on OCABR Guideline</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 1/2015</td>
</tr>
<tr>
<td>2</td>
<td>April 2015</td>
<td>2.1 (b)</td>
<td>Removal of ‘Acceptance of release certificate from NRA/NCL from country of origin’</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 1/2015</td>
</tr>
<tr>
<td>3</td>
<td>April 2015</td>
<td>2.1 Process flow</td>
<td>Change of process flow</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 4/2015</td>
</tr>
<tr>
<td>4</td>
<td>April 2015</td>
<td>2.2 (f) and 2.2.6</td>
<td>Include Airway Bill</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 1/2015</td>
</tr>
<tr>
<td>5</td>
<td>April 2015</td>
<td>2.2.2</td>
<td>Amend the link for list of WHO prequalified vaccine</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 1/2015</td>
</tr>
<tr>
<td>6</td>
<td>April 2015</td>
<td>2.6</td>
<td>Include information on shake test</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 2/2015</td>
</tr>
<tr>
<td>7</td>
<td>April 2015</td>
<td>2.9 Table 1</td>
<td>Revised timeline</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 1/2015</td>
</tr>
<tr>
<td>8</td>
<td>April 2015</td>
<td>2.10.2</td>
<td>Removal of ‘A separate bankdraft/banker’s cheque/MO/PO is necessary for each application lot’</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 1/2015</td>
</tr>
<tr>
<td>9</td>
<td>April 2015</td>
<td>4.1 Appendix 1</td>
<td>Change of application form for Vaccine Lot Release to version 2 (Effective date 1 May 2015)</td>
<td></td>
<td>Task Force Biological Lot Release Meeting No. 5/2015</td>
</tr>
<tr>
<td>NO.</td>
<td>REVISION</td>
<td>SECTION/ APPENDIX</td>
<td>DETAILS</td>
<td>REFERENCE</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>----------------</td>
<td>------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>December 2016</td>
<td>Whole document</td>
<td>Change of name from “National Pharmaceutical Control Bureau (NPCB)” to “National Pharmaceutical Regulatory Agency (NPRA)”</td>
<td>Task Force Biological Lot Release Meeting No. 6/2016</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>December 2016</td>
<td>2.3</td>
<td>Include the requirement to use electronic temperature monitoring devices</td>
<td>Task Force Biological Lot Release Meeting No. 6/2016</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>December 2016</td>
<td>2.6</td>
<td>Include additional requirement for Exceptional case application</td>
<td>Task Force Biological Lot Release Meeting No. 6/2016</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>December 2016</td>
<td>Appendix 1</td>
<td>Change of application form for Vaccine Lot Release to version 3 (Effective date 1 December 2016)</td>
<td>Task Force Biological Lot Release Meeting No. 10/2016</td>
<td></td>
</tr>
</tbody>
</table>